News

Deal Announcements

Cambria Pharmaceuticals Secures Series A Funding

Wednesday, April 23, 2008 5:38:00 AM PDT | VentureDeal Staff
WOBURN, MA -- Cambria Pharmaceuticals, Inc. announced that it has raised $5.4 million in its first round of venture capital financing.

Cambria is discovering treatments for "serious and progressively disabling neurological disorders."  The company uses recently-discovered genetic basis information to engineer new solutions, and intends to focus on ALS (Lou Gehrig's disease" and other serious diseases.

Biogen Idec New Ventures, CommonAngels of Boston and a number of individual investors invested in the round. 

The company will use the funding to advance its lead program in ALS through the clinical trial process.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1